| | Sandig et al |
|----|-------------------------------------------------------------------------------------------------------------------------------------|
| 1 | TITLE PAGE |
| 2 | |
| 3 | Original Article |
| 4 | |
| 5 | Fibronectin is a Th1-specific molecule in humans. |
| 6 | |
| 7 | Hilary Sandig, PhD, ^a Joanne McDonald, BSc, ^a Jane Gilmour, PhD, ^a Matthew Arno, PhD, ^b |
| 8 | Tak H Lee, MD ScD, ^a and David J Cousins, PhD ^a |
| 9 | |
| 10 | ^a MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, |
| 11 | Guy's Hospital, London, United Kingdom |
| 12 | ^b Genomics Centre, School of Biomedical and Health Sciences, King's College London, 150 |
| 13 | Stamford Street, London, United Kingdom. |
| 14 | |
| 15 | Corresponding author: |
| 16 | Dr David Cousins, PhD |
| 17 | MRC & Asthma UK Centre in Allergic Mechanisms of Asthma |
| 18 | Division of Asthma, Allergy and Lung Biology |
| 19 | King's College London |
| 20 | 5 th Floor Tower Wing |
| 21 | Guy's Hospital, London |
| 22 | SE1 9RT, UK |
| 23 | Tel: +44 207 188 0595 |
| 24 | Fax: +44 207 403 8640 |
| 25 | Email: david.cousins@kcl.ac.uk |
| | |

- 26 Declaration of sources of funding: This work was funded by grants from the Medical
- 27 Research Council (G9536930), Asthma UK, Guy's & St. Thomas' Charity, and The Friends
- of Guy's Hospital. JM is supported by a Medical Research Council PhD studentship. The
- 29 authors also acknowledge financial support from the Department of Health via the National
- 30 Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to
- 31 Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London.

32

33 Word Count: 3478

34 Abstract

Background: Th1 cell mediated immunity is essential for host defense against a variety of
intracellular pathogens such as mycobacteria, salmonella and leishmania. A major Th1
mediated effector mechanism involves the IFNγ-induced killing of the pathogen by infected

38 macrophages.

39 Objectives: The range of known Th1-specific effector molecules is limited, especially in

40 humans. We sought to identify novel effector molecules that may be involved in Th1-

41 mediated pathogen clearance.

42 Methods: We performed microarray-based analysis of human Th1 and Th2 cells to identify

43 Th1-specific molecules. These analyses identified the extracellular matrix molecule

44 fibronectin as a highly expressed Th1-specific molecule. We examined the expression of

45 fibronectin in a variety of human cell types by real-time RT-PCR, ELISA and Western

46 blotting. We also studied the role of fibronectin in modulating monocyte phenotype by *in*

47 *vitro* culture.

Results: We show that human Th1 cells constitutively express and secrete fibronectin after *in vitro* differentiation from naïve precursors. Furthermore, we demonstrate that *ex vivo* human Th1 cells selectively express fibronectin when compared to Th2 cells. The predominant isoform of fibronectin expressed by Th1 cells contains additional domains of the protein responsible for $\alpha 4\beta 1$ integrin binding and activation of Toll-like receptor 4. We show that treatment of monocytes with Th1 cell-derived fibronectin induces expression of the pro-

54 inflammatory cytokine IL-6, whilst inhibiting IL-10 expression.

Conclusions: Since fibronectin also plays a major role in the attachment and opsonisation of
numerous intracellular pathogens we propose that it may be a critical molecule produced by
Th1 cells involved in pathogen eradication.

| 59 | Key Messages | | | | | | |
|----|-----------------------------------------------------------------------------------------|--|--|--|--|--|--|
| 60 | • Human Th1 cells selectively express high levels of fibronectin | | | | | | |
| 61 | • Th1-cell derived fibronectin induces a pro-inflammatory phenotype in monocytes | | | | | | |
| 62 | • Fibronectin may play a important role in pathogen clearance by macrophages | | | | | | |
| 63 | | | | | | | |
| 64 | Capsule Summary | | | | | | |
| 65 | Th1 cell mediated immunity is essential for host defense but also contributes to the | | | | | | |
| 66 | pathogenesis of autoimmune disease. We show here that fibronectin is a pro-inflammatory | | | | | | |
| 67 | Th1-specific molecule and may represent a novel therapeutic target. | | | | | | |
| 68 | | | | | | | |
| 69 | Key words | | | | | | |
| 70 | Th1 cell, fibronectin, opsonisation, TLR4, integrin, monocyte. | | | | | | |
| 71 | | | | | | | |
| 72 | Abbreviations | | | | | | |
| 73 | APC: antigen presenting cell | | | | | | |
| 74 | EDA: Extra domain A of fibronectin | | | | | | |
| 75 | EDB: Extra domain B of fibronectin | | | | | | |
| 76 | FN1: fibronectin | | | | | | |
| 77 | IFNγ: Interferon-gamma | | | | | | |
| 78 | IL-: Interleukin | | | | | | |
| 79 | PBMCs: Peripheral blood mononuclear cells | | | | | | |
| 80 | PMA: Phorbol myristate acetate | | | | | | |
| 81 | STAT: signal transducer and activator of transcription | | | | | | |
| 82 | Th: T-helper | | | | | | |
| 83 | TLR: Toll-like receptor | | | | | | |
| 84 | | | | | | | |

85 INTRODUCTION

86 CD4⁺ T-lymphocytes can be subdivided into at least two functionally distinct subsets. Th1 and Th2, based upon the cytokines they secrete upon exposure to antigen¹. Th1 cells produce 87 88 IFN γ , TNF α and lymphotoxin and orchestrate phagocyte dependent immune responses to intracellular pathogens². Th2 cells secrete IL-4, IL-5 and IL-13, induce IgE production, and 89 90 promote eosinophil effector functions in response to extracellular helminth parasites. Both 91 cell types have been implicated in disease when induced inappropriately. Th1 cells often 92 reside at the sites of chronic inflammatory diseases such as rheumatoid arthritis and multiple 93 sclerosis whilst Th2 cells have been implicated in the pathogenesis of allergic diseases and asthma. Recent studies have identified a third subset of CD4⁺ effector T-cells, termed Th17, 94 95 that secrete IL-17 and IL-22 and are involved in pro-inflammatory responses to extracellular bacterial and fungal pathogens³. 96

97 Several factors influence the development of effector T-cells from naïve precursors 98 including the strength of stimulus, the nature of the accessory cells and the cytokine milieu. 99 The transcription factors that govern Th1/Th2 differentiation have been identified: Th1 cell differentiation is induced by IL-12 from APCs and is controlled by the transcription factor T-100 bet; whereas Th2 differentiation is induced by IL-4 and controlled by GATA3^{4, 5}. Th1-101 102 mediated immune responses are critical for the resistance to a variety of infectious pathogens. 103 Genetic defects in the Th1 pathway have demonstrated the key role played by this cell type in 104 protective responses to pathogens. Mutations in the genes encoding IL-12p40, IL-12R β 1, 105 IFNyR1, IFNyR2 and STAT1 can all cause primary immunodeficiencies in humans resulting in susceptibility to a variety of normally weakly pathogenic bacteria⁶. 106

In recent years numerous studies have examined the differentiation of Th1 and Th2
 cells from naïve precursors and several approaches have been used to identify effector
 molecules differentially expressed by these subsets⁷⁻⁹. The majority of these studies were

performed on murine T-cells and have provided considerable insight into the mechanisms 110 111 that control Th1/Th2 differentiation and function. Despite the considerable body of work 112 investigating Th1 cell mediated disease, very few Th1-specific effector molecules have been identified. We have performed a microarray-based analysis of human Th1/Th2 cells to 113 114 identify molecules selectively expressed by these cell types. Here, we identify the extracellular matrix molecule fibronectin (FN1) as a gene expressed specifically by Th1 cells. 115 116 *In vitro* differentiation analyses show that FN1 is selectively induced during Th1 117 differentiation and is constitutively expressed by highly polarized Th1 cells. We demonstrate 118 that ex vivo human Th1 cells selectively express FN1 when compared to ex vivo Th2 cells. 119 Th1 cells express an unusual isoform of fibronectin which is associated with leukocyte 120 extravasation, bacterial opsonisation and activation of the TLR4 pattern recognition receptor. 121 Furthermore, we show that Th1 cell derived fibronectin modulates the cytokine expression 122 profile of monocytes, inducing a pro-inflammatory phenotype expressing increased levels of 123 IL-6 and reduced levels of IL-10.

124 METHODS

125 Cell isolation, Th1/Th2 differentiation and flow cytometry

126 In vitro differentiation of human Th1/Th2 cells and intracellular staining was performed as

127 previously reported¹⁰ and is described in detail in the Online Repository. *Ex vivo* cell

128 isolations were performed by magnetic selection or flow cytometry and are described in

129 detail in the Online Repository.

130

131 RNA isolation, RT-PCR and microarray analyses

132 RNA was isolated and RT-PCR performed as previously reported¹¹ and is described in detail

133 in the Online Repository. Microarray analyses were performed using Affymetrix U133 plus 2

134 microarrays according to the manufacturers instructions. Details are described in the Online

135 Repository.

136

137 Fibronectin ELISA and Western Blotting

138 Fibronectin ELISA on tissue culture supernatants were performed using the QuantiMatrixTM

139 Human Fibronectin ELISA kit (Chemicon) or the Human Fibronectin Immunoassay Kit

140 (Biomedical Technologies Inc.) according to the manufacturer's instructions. Since bovine

141 serum contains plasma fibronectin that could cross react with the immunoassay, culture

142 media containing 10% FBS was also examined to determine the background level of

143 fibronectin present.

144 Cytoplasmic protein fractions from Th1/Th2 cells differentiated for 28 days were 145 isolated as previously described using the NE-PER protein isolation kit (Pierce) according to 146 the manufacturer's instructions¹¹. Cytoplasmic fractions and tissue culture supernatants were 147 loaded onto NuPAGE 4-12% gels (Invitrogen) according to the manufacturer's instructions. 148 Western blotting and ECL detection were performed as previously described¹¹. Primary

149 antibodies used were: rabbit polyclonal anti-Fibronectin (H-300; Santa Cruz Biotechnology),

150 mouse monoclonal anti-GAPDH (6C5; Abcam). Secondary detection antibodies were HRP-

151 conjugated goat anti-mouse IgG (sc-2005; Santa Cruz Biotechnology) and goat anti-rabbit

152 IgG (sc-2004; Santa Cruz Biotechnology).

153

154 Fibronectin purification

Th1 cell supernatants were loaded onto a gelatin-sepharose column (GE Healthcare) and flow through was collected. After washing the column with PBS, fibronectin was eluted with 1M arginine. Sequential elutions were collected, combined and concentrated using a Vivaspin microconcentrator with molecular weight cut off of 50 kDa (Vivascience). Excess arginine was removed by sequential washes in PBS. Purity of the fibronectin fractions was assessed by SDS-PAGE, Coomassie staining and Western blotting.

161

162 Monocyte isolation and culture

163 Peripheral blood monocytes were isolated from PBMCs using the MyPure monocyte

164 isolation kit (Invitrogen). Purities were routinely 95% as assessed by FACs. Monocytes were

165 cultured overnight in RPMI 1640 supplemented with 10% FBS, glutamine, penicillin and

166 streptomycin as described above. Where indicated, recombinant human IFNγ (R & D

167 Systems) was added at a final concentration of 50ng/ml and purified Th1 cell derived

168 fibronectin was added at a final concentration of 100 ng/ml.

169 RESULTS

170 Microarray Analysis Reveals Th1-specific Fibronectin Transcription

171 We have previously reported a method to generate highly polarized human Th1 and Th2 cell populations from naïve CD4⁺ T-cells after four weeks in culture¹⁰. Using these culture 172 173 conditions we produced cells with the characteristic expression patterns of Th1 and Th2 cytokines upon activation. Intracellular cytokine staining of the *in vitro* differentiated Th1 174 and Th2 cells demonstrated that prior to stimulation neither population expressed the Th1 175 176 cytokine IFNy or the Th2 cytokines IL-4, IL-5 and IL-13 (see Figure E1 in the Online Repository). Upon acute activation with PMA and ionomycin at least 99% of the Th1 cells 177 178 expressed IFN γ with negligible IFN γ expression by the Th2 cells (Figure E1, upper panel). 179 Approximately 80% of the Th2 cells expressed IL-13 and multicolour analysis demonstrated that there was considerable coexpression of IL-4 and IL-5 (Figure E1, lower panels). The Th1 180 181 cells did not express Th2 cytokines. These cells were used to perform comparative 182 microarray expression analysis for all known human genes using Affymetrix U133 plus 2 183 microarrays. In these analyses, fibronectin was identified as being highly selectively 184 expressed by Th1 cells (see Table EI in the Online Repository). The mean difference between 185 transcription levels of FN1 in Th1 and Th2 cells is 1,106 fold. Analysis of the microarray 186 data showed that other extracellular matrix molecules, such as collagen, fibrillin, laminin and 187 elastin were either not differentially expressed or not expressed at all (Table E1). This 188 indicates that of the extracellular matrix molecules only fibronectin is selectively transcribed 189 by Th1 cells. Further analysis of the microarray data showed that the gene encoding AICAR 190 Transformylase/IMP Cyclohydrolase (ATIC), immediately adjacent to fibronectin on human 191 chromosome 2, is also not differentially expressed in Th1 versus Th2 cells. This suggests that 192 the Th1-specific transcription of fibronectin is not caused by the adventitious location of the 193 FN1 gene in a Th1-specific chromosomal domain.

Th1-specific expression of Fibronectin by *in vitro* differentiated human T-helper cells 194 195 To further investigate the Th1-specific transcription of the FN1 gene we analyzed highly 196 differentiated Th1 and Th2 cells by quantitative real-time RT-PCR (Figure 1A). As expected, 197 highly Th1-specific and activation responsive transcription of IFNy was observed in cells 198 cultured for 28 days. Furthermore, Th2-specific transcription of IL-4, IL-5 and IL-13 was 199 found upon Th2 cell activation (Figure 1A). Analysis of these samples demonstrated Th1-200 specific transcription of the FN1 mRNA (Figure 1A). Interestingly, the FN1 mRNA appears 201 to be constitutively transcribed by Th1 cells prior to activation, in contrast to the cytokine genes. Unstimulated Th1 cells express 1,259 fold more FN1 mRNA than unstimulated Th2 202 203 cells. Upon activation the FN1 mRNA levels appeared to decrease slightly in Th1 cells with 204 no notable expression in the activated Th2 cells. These data confirm the initial microarray analyses and indicate that human Th1 cells constitutively transcribe the FN1 gene. 205

206 We then examined the transcription of the FN1 gene during the process of in vitro 207 differentiation by real-time RT-PCR on samples from day 14, 21 and 28 of the four-week 208 culture period (Figure 1B). We observed constitutive expression of the FN1 mRNA at each time point of Th1 differentiation with a steady increase in the FN1 mRNA levels as 209 210 differentiation proceeded. The profile of FN1 mRNA expression during Th1 differentiation 211 parallels the IFNy mRNA levels with the exception that FN1 is constitutively transcribed. 212 Once again there was negligible FN1 mRNA detected at any time point during Th2 213 differentiation although mRNA for the Th2 cytokine genes steadily increased during the 214 culture period (Figure 1B). The increase in FN1 levels during Th1 differentiation suggests that the ability to transcribe FN1 is a T-helper cell characteristic acquired during Th1 215 216 differentiation rather than a characteristic lost during Th2 differentiation. 217 To investigate whether fibronectin protein is expressed by the Th1 cells we performed

218 ELISA assays for soluble fibronectin in tissue culture supernatants from the highly polarized

Th1 and Th2 cultures (Figure 1C). Soluble fibronectin was readily detectable by ELISA in
the Th1 supernatants from cells differentiated for 28 days (478 ng/ml). No detectable
fibronectin was identified in the Th2 cell supernatants above the amounts present in the
culture media (which contains FBS). Analysis of cell supernatants taken during the *in vitro*differentiation clearly show that the protein levels mirror the mRNA levels, with a steady
increase during Th1 differentiation and no detectable fibronectin in the Th2 cultures (Figure 1D).

226 Fibronectin is a complex dimeric glycoprotein containing two subunits of approximately 250 kDa each^{12, 13}. Alternative splicing produces several different molecules 227 228 containing variable numbers of Type III FN repeats and also truncated fibronectin molecules. 229 To examine the size of the Th1 cell specific fibronectin protein we performed western blots of cell extracts and tissue culture supernatants (Figure 1E & F). Western blots of cytoplasmic 230 231 extracts from Th1 and Th2 cells readily detected a single Th1-specific band of over 250 kDa (Figure 1E). Interestingly, the amount of fibronectin in the Th1 cytoplasmic extract decreased 232 upon activation. There was no detectable fibronectin in the Th2 cytoplasmic extracts. 233 234 Examination of the cell culture supernatants by Western blotting also revealed a Th1-specific 235 band of the same size as the cytoplasmic protein (Figure 1F). A faint band is detectable in the 236 Th2 supernatants but this represents cross-reactivity with the bovine fibronectin in the culture 237 medium from the FBS. These data confirm that the Th1 cells constitutively express full-238 length fibronectin and suggest that fibronectin is secreted by the Th1 cells upon activation. 239 Fibronectin is selectively expressed by ex vivo human Th1 cells 240 241 To determine whether the Th1-specific expression of FN1 that we observe *in vitro* is 242 observed in cells directly isolated from human subjects, we have isolated both Th1 and Th2

243 populations from peripheral blood. *Ex vivo* Th1 cells were isolated by FACS sorting

12

| 244 | $CD3^{+}CD4^{+}IFN\gamma^{+}$ T-cells and <i>ex vivo</i> Th2 cells were isolated by FACS sorting $CD3^{+}CD4^{+}IL-$ |
|-----|----------------------------------------------------------------------------------------------------------------------|
| 245 | 13^+ T-cells (Figure 2A). The relative levels of expression by these cells of IFN γ , IL-13 and |
| 246 | FN1 were assessed by real-time RT-PCR (Figure 2B). The data clearly show that FN1 is |
| 247 | highly selectively expressed by the CD4 ⁺ IFN γ^+ population in a manner similar to IFN γ , |
| 248 | whereas IL-13 is selectively expressed by the $CD4^+$ IL-13 ⁺ cell population. Similar results |
| 249 | were obtained using <i>ex vivo</i> cells from atopic donors (data not shown). These results show |
| 250 | that <i>ex vivo</i> Th1 cells selectively express the FN1 gene and that the Th1-specific expression |
| 251 | observed after in vitro differentiation reflects expression of this gene by ex vivo Th1 cells. |
| 252 | |
| 253 | Several alternatively spliced fibronectin isoforms are expressed by Th1 cells |
| 254 | The FN1 gene contains at least forty five exons and is subject to several alternative splicing |
| 255 | events. These splicing events introduce additional Type III fibronectin repeats into the |
| 256 | protein. There are three sites at which alternative splicing occurs, termed extra domain A |
| 257 | (EDA), EDB and the variable (V) region (see Figure E2A in the Online Repository). The |
| 258 | EDA and EDB regions are absent from most adult tissue but are expressed during embryonic |
| 259 | development, tissue injury, inflammation and angiogenesis ¹³ . The variable region is |
| 260 | differentially expressed in a variety of tissues. We have examined the Th1-specific FN1 |
| 261 | transcripts by RT-PCR and sequencing to ascertain which splicing events occur in Th1 cells. |
| 262 | RT-PCR using primers spanning the EDB region identified a single fragment of 296 bp, the |
| 263 | size expected for transcripts with the EDB exon absent (see Figure E2B & C in the Online |
| 264 | Repository). Cloning and sequencing of the PCR product confirmed that the Th1-specific |
| 265 | FN1 transcript does not contain the EDB exon (data not shown). |
| 266 | RT-PCR using primers spanning the EDA and V regions identified three major |
| 267 | products of different intensities between 1000 bp and 1700 bp (see Figure E2B & D in the |

268 Online Repository). Cloning and sequencing of these PCR products identified a range of

different splicing events. The EDA region is absent from some cloned transcripts but is 269 270 present in 84% of clones identified. Inclusion of the EDA region of fibronectin introduces a binding site for integrins $\alpha 9\beta 1$ and $\alpha 4\beta 1^{14}$. Germline deletion of the EDA exon in the mouse 271 causes defects in wound healing and also defects in accumulation of extravasated 272 macrophages during acute inflammation^{15, 16}. Recent work has shown that the EDA region of 273 FN1 also acts as an endogenous ligand for the pattern recognition receptor TLR4 and causes 274 NF- κ B activation and secretion of IL-12 and TNF α by dendritic cells and macrophages^{17, 18}. 275 Sequencing of the V region reveals a complex pattern of exon usage (see Figure E2E 276 277 & F in the Online Repository). The V region of fibronectin contains at least two recognition sites for the $\alpha 4\beta 1$ integrin, the LDV and REDV motifs^{19, 20}. These motifs are present in the V 278 region sequences that we have identified (see Figure E2E & F in the Online Repository). The 279 α 4 β 1 integrin (also known as VLA-4) is expressed on lymphoid and myeloid cells and α 4 β 1 280 281 interactions with fibronectin are important for leukocyte extravasation during acute inflammation (reviewed in Ref¹²). 282

To further examine the Th1-specific expression of the EDA-containing fibronectin 283 isoform in the context of immune cell function we have screened a large panel of innate and 284 adaptive immune cell types for expression of both total fibronectin and EDA containing 285 mRNA by quantitative real-time RT-PCR (Figure 3). Figure 3A clearly shows that of all the 286 cell types examined only Th1 cells express high levels of fibronectin mRNA. When 287 specifically examining the expression of the EDA exon a small amount of expression was 288 289 detected in CD4+CD25+ T-cells, probably representing the activated T-cells in the periphery. A small amount of EDA specific fibronectin was also detected in NKT-cells but the 290 291 predominant cell type expressing EDA specific fibronectin was the Th1 cell (Figure 3B). 292

294

295

Th1-cell derived fibronectin modulates cytokine expression by monocytes 296 To investigate the potential function of Th1 cell derived fibronectin we purified fibronectin 297 298 from Th1 cell culture supernatants by affinity chromatography taking advantage of the specific binding of fibronectin to gelatin-sepharose²¹. Th1 cell supernatants were mixed with 299 300 a gelatin-sepharose slurry, and the bound fibronectin washed extensively, before elution with 301 arginine (Figure 4A). We examined the effect of fibronectin on peripheral blood monocytes 302 which express both TLR4 and $\alpha 4\beta 1$ integrin, two of the receptors known to bind to 303 fibronectin including the EDA region. Monocytes were isolated from PBMCs by negative 304 magnetic selection and cultured overnight either in culture media or with IFNy. After overnight culture the monocytes were treated with Th1 cell derived fibronectin for 4 hours 305 306 before harvesting for RNA isolation and quantitative real-time RT-PCR to examine cytokine gene expression. In combination with IFNy, fibronectin induced a significant and synergistic 307 308 upregulation of IL-6 mRNA that was not observed with either fibronectin or IFNy alone 309 (Figure 4B). In contrast fibronectin treatment alone was sufficient to downregulate IL-10 310 mRNA expression (Figure 4C). A similar trend was observed in the presence of IFNy although it did not reach statistical significance (Figure 4C). These results demonstrate that 311 312 Th1 cell derived fibronectin can modulate monocyte cytokine transcription promoting the 313 expression of the pro-inflammatory cytokine IL-6 whilst downregulating expression of the 314 regulatory cytokine IL-10.

315 DISCUSSION

Our findings clearly demonstrate that human Th1 cells generated *in vitro* constitutively 316 express fibronectin at high levels. IFN γ -secreting CD4⁺ Th1 cells isolated directly *ex vivo* 317 also selectively express fibronectin compared to *ex vivo* IL-13⁺CD4⁺ Th2 cells. We have also 318 319 shown that fibronectin expressed by Th1 cells can promote the expression of the proinflammatory cytokine IL-6 by monocytes whilst downregulating IL-10 expression. We 320 321 propose that fibronectin is a new Th1-specific effector molecule based upon the multiple and 322 complex roles played by fibronectin in immune cell recruitment and function (Figure 6). The interaction between pathogens and fibronectin has long been recognized and a considerable 323 324 body of work has shown that many pathogens express specific fibronectin binding proteins including mycobacteria, staphylococcae and leishmania²²⁻²⁴. Several of these molecules are 325 virulence factors for pathogens and have been proposed to play an important role in bacterial 326 adherence and invasion at the site of injury^{25, 26}. By the same mechanism, fibronectin also 327 328 plays an important role in the opsonisation and engulfment of these pathogens by macrophages²⁷. Therefore expression of fibronectin by Th1 cells could promote clearance of 329 330 pathogenic microbes by macrophages which are also activated to kill phagocytosed bacteria 331 by Th1-cell derived IFNy.

332 Fibronectin also plays an important role in leucocyte extravasation during an 333 inflammatory response via binding to integrin $\alpha 4\beta 1$ on the surface of both lymphoid and myeloid cells¹². Therefore Th1-specific expression of fibronectin may also recruit other cell 334 types including macrophages and also more Th1 cells (Figure 5). It is interesting that Th2 335 cells do not bind to fibronectin, further emphasizing the Th1-specific nature of fibronectin²⁸. 336 337 It is also important to note that the Th1-specific isoforms of fibronectin containing EDA harbour several additional binding sites for integrin $\alpha 4\beta 1$ and $\alpha 9\beta 1$ and thus may promote 338 extravasation more effectively¹⁴. The EDA-containing isoforms of fibronectin are not 339

normally expressed in adult tissue but have been identified in response to tissue injury, 340 wound healing^{29, 30}, fibrosis³¹, and allograft transplantation³². EDA-fibronectin has also been 341 observed in the synovial fluid in rheumatoid arthritis^{33, 34}, in multiple sclerosis^{35, 36} and 342 psoriasis³⁷ all diseases with a significant Th1-mediated pathology. In these disease settings 343 344 the source of EDA-fibronectin has not been entirely clear with some evidence for macrophage or fibroblast involvement. Our work suggests that one source of EDA-345 346 fibronectin is likely to be the Th1 cell. Recent work using mutant mouse strains in which the 347 EDA exon was deleted has demonstrated that this region plays a role in wound healing and also in macrophage accumulation during inflammation^{15, 16}. It would be interesting to 348 349 examine the effect of deletion of the EDA region in Th1 mediated infectious disease mouse 350 models and autoimmune pathologies such as experimental autoimmune encephalomyelitis.

Recent work by two groups has shown that the EDA region of fibronectin expressed 351 by Th1 cells is an endogenous ligand for TLR4^{17, 18}. Ligation of TLR4 classically induces 352 NF-kB signaling and promotes Th1 immunity via stimulation of antigen presenting cells to 353 produce pro-inflammatory cytokines such as IL-6 and also $IL-12^{38}$. We have shown here that 354 the Th1-derived fibronectin containing the EDA region can induce IL-6 gene expression from 355 356 monocytes and also suppress IL-10 gene expression. The role of EDA-fibronectin as an 357 endogenous ligand for TLR4 and for integrin binding is particularly interesting in the light of 358 recent studies showing that the TLR4 signaling pathway is dependent upon integrin signaling to localize the adaptor molecule TIRAP to the plasma membrane in macrophages³⁹. It is 359 360 therefore possible that EDA-fibronectin can perform both roles in macrophage activation. 361 Elucidation of the relative roles of integrin and TLR4 signaling by Th1 derived 362 fibronectin in monocyte/macrophage activation will require further studies beyond the scope 363 of this report. Experiments to dissect the role of the different domains and their effect on 364 TLR4 and integrins will be technically challenging since fibronectin is a very large molecule

365 containing numerous domains with overlapping functions making the use of function366 blocking antibodies against each domain extremely difficult to interpret.

We have shown that human Th1 cells selectively express fibronectin at high levels 367 both *in vitro* and *ex vivo* when compared to Th2 cells and other immune cell types. It will be 368 369 interesting to examine pro-inflammatory Th17 cells for fibronectin expression once the methods for efficient generation of human Th17 cells have been characterized. The Th1-370 371 specific expression of fibronectin at first seems to contrast with data supporting a role for 372 fibronectin in Th2-mediated disease pathologies such as asthma, however it is likely that other cell types contribute to the fibronectin deposition seen in Th2 disease. In fact, although 373 374 it is clear that there is increased extracellular matrix deposition in the subepithelial reticular 375 basement membrane in asthma, there is little evidence of increased total or EDA-containing fibronectin in seasonal or chronic asthma⁴⁰. Collectively our data suggest that fibronectin can 376 function as a Th1-specific effector molecule. Germline deletion of fibronectin is lethal in 377 mice, which has hampered study of the function of this molecule *in vivo*. It would be 378 intriguing to examine the role of EDA-containing fibronectin in Th1 disease models in which 379 380 the EDA exon has been deleted.

381

382

383 Acknowledgments

We would like to thank David Richards for help with cell sorting, the research nurses Kheem
Jones and Cherylin Reinholtz for phlebotomy, and members of the Cousins laboratory for
insightful comments.

| 388 | Refer | ences |
|-----|-------|----------------------------------------------------------------------------------------|
| 389 | 1. | Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol |
| 390 | | 2002; 2:933-44. |
| 391 | 2. | O'Garra A, Robinson D. Development and function of T helper 1 cells. Adv Immunol |
| 392 | | 2004; 83:133-62. |
| 393 | 3. | McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. |
| 394 | | Immunity 2008; 28:445-53. |
| 395 | 4. | Ansel KM, Djuretic I, Tanasa B, Rao A. Regulation of Th2 differentiation and Il4 |
| 396 | | locus accessibility. Annu Rev Immunol 2006; 24:607-56. |
| 397 | 5. | Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating |
| 398 | | Th1 immune responses. Annu Rev Immunol 2003; 21:713-58. |
| 399 | 6. | Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, van Dissel |
| 400 | | JT. Genetics, cytokines and human infectious disease: lessons from weakly |
| 401 | | pathogenic mycobacteria and salmonellae. Nat Genet 2002; 32:97-105. |
| 402 | 7. | Lu B, Zagouras P, Fischer JE, Lu J, Li B, Flavell RA. Kinetic analysis of genomewide |
| 403 | | gene expression reveals molecule circuitries that control T cell activation and Th1/2 |
| 404 | | differentiation. Proc Natl Acad Sci U S A 2004; 101:3023-8. |
| 405 | 8. | Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1- |
| 406 | | specific cell surface protein Tim-3 regulates macrophage activation and severity of an |
| 407 | | autoimmune disease. Nature 2002; 415:536-41. |
| 408 | 9. | Rogge L, Bianchi E, Biffi M, Bono E, Chang SY, Alexander H, et al. Transcript |
| 409 | | imaging of the development of human T helper cells using oligonucleotide arrays. Nat |
| 410 | | Genet 2000; 25:96-101. |

| 411 | 10. | Cousins DJ, Lee TH, Staynov DZ. Cytokine coexpression during human TH1/TH2 |
|-----|-----|---------------------------------------------------------------------------------------|
| 412 | | cell differentiation: direct evidence for coordinated expression of th2 cytokines. J |
| 413 | | Immunol 2002; 169:2498-506. |
| 414 | 11. | Gilmour J, Cousins DJ, Richards DF, Sattar Z, Lee TH, Lavender P. Regulation of |
| 415 | | GM-CSF expression by the transcription factor c-Maf. J Allergy Clin Immunol 2007; |
| 416 | | in press. |
| 417 | 12. | Johansson S, Svineng G, Wennerberg K, Armulik A, Lohikangas L. Fibronectin- |
| 418 | | integrin interactions. Front Biosci 1997; 2:d126-46. |
| 419 | 13. | Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci 2002; 115:3861-3. |
| 420 | 14. | Liao YF, Gotwals PJ, Koteliansky VE, Sheppard D, Van De Water L. The EIIIA |
| 421 | | segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 |
| 422 | | providing a novel mechanism for regulating cell adhesion by alternative splicing. J |
| 423 | | Biol Chem 2002; 277:14467-74. |
| 424 | 15. | Muro AF, Chauhan AK, Gajovic S, Iaconcig A, Porro F, Stanta G, et al. Regulated |
| 425 | | splicing of the fibronectin EDA exon is essential for proper skin wound healing and |
| 426 | | normal lifespan. J Cell Biol 2003; 162:149-60. |
| 427 | 16. | Tan MH, Sun Z, Opitz SL, Schmidt TE, Peters JH, George EL. Deletion of the |
| 428 | | alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood |
| 429 | | 2004; 104:11-8. |
| 430 | 17. | Lasarte JJ, Casares N, Gorraiz M, Hervas-Stubbs S, Arribillaga L, Mansilla C, et al. |
| 431 | | The extra domain A from fibronectin targets antigens to TLR4-expressing cells and |
| 432 | | induces cytotoxic T cell responses in vivo. J Immunol 2007; 178:748-56. |
| 433 | 18. | Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra |
| 434 | | domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276:10229- |
| 435 | | 33. |

| 436 | 19. | Guan JL, Hynes RO. Lymphoid cells recognize an alternatively spliced segment of |
|-----|-----|--------------------------------------------------------------------------------------|
| 437 | | fibronectin via the integrin receptor alpha 4 beta 1. Cell 1990; 60:53-61. |
| 438 | 20. | Mould AP, Komoriya A, Yamada KM, Humphries MJ. The CS5 peptide is a second |
| 439 | | site in the IIICS region of fibronectin recognized by the integrin alpha 4 beta 1. |
| 440 | | Inhibition of alpha 4 beta 1 function by RGD peptide homologues. J Biol Chem 1991; |
| 441 | | 266:3579-85. |
| 442 | 21. | Vuento M, Vaheri A. Purification of fibronectin from human plasma by affinity |
| 443 | | chromatography under non-denaturing conditions. Biochem J 1979; 183:331-7. |
| 444 | 22. | Alexander J, Satoskar AR, Russell DG. Leishmania species: models of intracellular |
| 445 | | parasitism. J Cell Sci 1999; 112 Pt 18:2993-3002. |
| 446 | 23. | Schorey JS, Holsti MA, Ratliff TL, Allen PM, Brown EJ. Characterization of the |
| 447 | | fibronectin-attachment protein of Mycobacterium avium reveals a fibronectin-binding |
| 448 | | motif conserved among mycobacteria. Mol Microbiol 1996; 21:321-9. |
| 449 | 24. | Schwarz-Linek U, Werner JM, Pickford AR, Gurusiddappa S, Kim JH, Pilka ES, et |
| 450 | | al. Pathogenic bacteria attach to human fibronectin through a tandem beta-zipper. |
| 451 | | Nature 2003; 423:177-81. |
| 452 | 25. | Finlay BB, Cossart P. Exploitation of mammalian host cell functions by bacterial |
| 453 | | pathogens. Science 1997; 276:718-25. |
| 454 | 26. | Hauck CR, Ohlsen K. Sticky connections: extracellular matrix protein recognition and |
| 455 | | integrin-mediated cellular invasion by Staphylococcus aureus. Curr Opin Microbiol |
| | | |

456 2006; 9:5-11.

457 27. Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu
458 Rev Immunol 2002; 20:825-52.

28.

459

460

461

- 462 29. Ffrench-Constant C, Van de Water L, Dvorak HF, Hynes RO. Reappearance of an
 463 embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell
 464 Biol 1989; 109:903-14.
- Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM. Expression of
 variant fibronectins in wound healing: cellular source and biological activity of the
 EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994; 127:2037-48.
- 468 31. Kuhn C, 3rd, Boldt J, King TE, Jr., Crouch E, Vartio T, McDonald JA. An
- 468 31. Kuhn C, 3rd, Boldt J, King TE, Jr., Crouch E, Vartio T, McDonald JA. An
- 469 immunohistochemical study of architectural remodeling and connective tissue

470 synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989; 140:1693-703.

- 471 32. Coito AJ, Brown LF, Peters JH, Kupiec-Weglinski JW, van de Water L. Expression
 472 of fibronectin splicing variants in organ transplantation: a differential pattern between
 473 rat cardiac allografts and isografts. Am J Pathol 1997; 150:1757-72.
- 474 33. Hino K, Shiozawa S, Kuroki Y, Ishikawa H, Shiozawa K, Sekiguchi K, et al. EDA-
- 475 containing fibronectin is synthesized from rheumatoid synovial fibroblast-like cells.

476 Arthritis Rheum 1995; 38:678-83.

- 477 34. Peters JH, Carsons S, Kalunian K, McDougall S, Yoshida M, Ko F, et al. Preferential
 478 recognition of a fragment species of osteoarthritic synovial fluid fibronectin by
- antibodies to the alternatively spliced EIIIA segment. Arthritis Rheum 2001; 44:2572-
- 480 85.
- 481 35. Sobel RA. The extracellular matrix in multiple sclerosis lesions. J Neuropathol Exp
 482 Neurol 1998; 57:205-17.

- 483 36. Sobel RA, Mitchell ME. Fibronectin in multiple sclerosis lesions. Am J Pathol 1989;
 484 135:161-8.
- Ting KM, Rothaupt D, McCormick TS, Hammerberg C, Chen G, Gilliam AC, et al.
 Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in
 the dermal-epidermal junction of psoriatic uninvolved skin. J Invest Dermatol 2000;
- 488 114:706-11.
- 489 38. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and
 490 acquired immunity. Nat Immunol 2001; 2:675-80.
- 491 39. Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls
 492 Toll-like receptor signaling. Cell 2006; 125:943-55.
- 493 40. Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA. Tenascin is
 494 increased in airway basement membrane of asthmatics and decreased by an inhaled
 495 steroid. Am J Respir Crit Care Med 1997; 156:951-8.
- 496
- 770
- 497
- 498

499

Figure legends

Figure 1. Th1-specific expression of fibronectin. (A) FN1 mRNA is selectively expressed 500 by Th1 cells. (R) resting (A) activated. Data shown are the mean ± SEM, n=4. (B) FN1 501 502 mRNA is induced during Th1 differentiation. Representative of two experiments. (C & D) 503 Fibronectin is secreted by Th1 cells. Fibronectin ELISA of supernatants. (C) mean \pm SEM, 504 n=4. (D) Representative of two experiments. (E & F) Western blotting of cytoplasmic 505 extracts and cell culture supernatants, (-) resting, (+) activated. 506 507 Figure 2. *Ex vivo* Th1 cells selectively express fibronectin. *Ex vivo* Th1 and Th2 cells were 508 isolated based on the expression of CD3, CD4 and IFNy or IL-13. (A) FACS plots show pre 509 and post sort profiles. (B) RT-PCR on sorted samples, mean± SEM, n=3. Gene expression is 510 shown relative to one biological replicate (Th1 for IFNy and FN1 and Th2 for IL-13). 511 Figure 3. Expression of fibronectin by immune cell types. Real-time RT-PCR for total 512 fibronectin (A) and EDA-fibronectin (B) mRNA in a panel of immune cell types. Cell types 513 514 were isolated by sorting from PBMCs or PMNs as described in methods, *in vitro* generated 515 Th1 and Th2 cells are also shown. R, resting cells; A, activated cells (PMA/Ionomycin). 516 517 Figure 4. Th1 cell derived fibronectin modulates monocyte gene expression. (A). Monocytes were cultured overnight with or without IFNy as indicated. After overnight 518 519 incubation fibronectin (light bars) or PBS (dark bars) was added for 4 hrs. Quantitative realtime RT-PCR was performed for IL-6 (B) and IL-10 (C). Statistical analysis: 2 way ANOVA 520 521 with Tukey post test $p<0.05 \approx p<0.01$. 522

- 523 Figure 5. Model for the role of fibronectin in Th1-cell functions. FnBP, fibronectin
- 524 binding protein; TLR4, toll-like receptor 4; $\alpha 4\beta 1$, integrin $\alpha 4\beta 1$; MØ, macrophage.



Figure 1 Sandig et al.







Figure 2 Sandig et al.





Figure 3 Sandig et al.





Figure 4 Sandig et al.



Figure 5 Sandig et al.

| | Sandig et al | 1 |
|----|-------------------------------------------------------------------------------------------------------------------------------------|---|
| 1 | ONLINE REPOSITORY | |
| 2 | | |
| 3 | TITLE PAGE | |
| 4 | | |
| 5 | Original Article | |
| 6 | | |
| 7 | Fibronectin is a Th1-specific molecule in humans. | |
| 8 | | |
| 9 | Hilary Sandig, PhD, ^a Joanne McDonald, BSc, ^a Jane Gilmour, PhD, ^a Matthew Arno, PhD, ^b | |
| 10 | Tak H Lee, MD ScD, ^a and David J Cousins, PhD ^a | |
| 11 | | |
| 12 | ^a MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, | |
| 13 | Guy's Hospital, London, United Kingdom | |
| 14 | ^b Genomics Centre, School of Biomedical and Health Sciences, King's College London, 150 | |
| 15 | Stamford Street, London, United Kingdom. | |
| 16 | | |
| 17 | Corresponding author: | |
| 18 | Dr David Cousins, PhD | |
| 19 | MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Division of Asthma, Allerg | y |
| 20 | and Lung Biology, King's College London, 5th Floor Tower Wing | |
| 21 | Guy's Hospital, London | |
| 22 | SE1 9RT, UK | |
| 23 | Tel: +44 207 188 0595 | |
| 24 | Fax: +44 207 403 8640 | |
| 25 | Email: david.cousins@kcl.ac.uk | |

26 METHODS

27 Th1/Th2 cell differentiation

Venous blood was taken from non-atopic healthy human volunteers using heparin as an 28 anticoagulant. Ethical approval for the use of human volunteers in this study was obtained 29 from the institutional ethical review committee. PBMCs were isolated using Lymphoprep[®] 30 (Nycomed) according to the manufacturer's instructions. CD4⁺ T-cells were isolated from 31 PBMCs using a CD4 Positive Isolation Kit (Invitrogen) according to the manufacturer's 32 instructions. Naïve CD45RA⁺ cells were purified from CD4⁺ cells by depletion of CD45RO⁺ 33 cells using mouse anti-human CD45RO antibody (UCHL1; BDBiosciences; 0.5µg/1x10⁶ 34 cells) and rat anti-mouse IgG Dynabeads[®] (Invitrogen) according to the manufacturer's 35 instructions. The purity of naïve cell populations were assessed by FACs as previously 36 described^{E1} and were at least 99% CD4⁺CR45RA⁺. 37 Purified CD45RA⁺ cells $(1 \times 10^{6} / \text{ml})$ were cultured in RPMI 1640 (Invitrogen) 38 supplemented with 10% FCS, 2 mM L-glutamine (Invitrogen), 100 U/ml penicillin 39 (Invitrogen), and 100 µg/ml streptomycin (Invitrogen). Cells were stimulated with plate-40 41 bound anti-CD3 (1µg/ml; clone OKT3) and anti-CD28 (2µg/ml; clone 15E8; Sanquin), rIL-2 (50U/ml; Eurocetus) and anti-IL-10 (5µg/ml; clone JES3-9D7; BDBiosciences). To direct 42 Th1 differentiation, rIL-12 (2.5ng/ml; R&D Systems) and anti-IL-4 (5µg/ml; clone MP4-43 25D2; BDBiosciences) were added. For Th2 differentiation, rIL-4 (12.5ng/ml; R&D 44 Systems) and anti-IFNy (5µg/ml; clone B-B1; Biosource) were added. After four days, the 45 cells were expanded under the same conditions in the absence of anti-CD3 or anti-CD28. 46

47 Cells were then re-stimulated every seven days. When required, cells were activated with

48 PMA (5ng/ml; Sigma) and ionomycin (500ng/ml; Calbiochem) for 4 hours.

49

51

52 Intracellular cytokine staining

Resting cells were activated with PMA (5ng/ml) and ionomycin (500ng/ml) for 4 hours, 53 monensin (2 µM; Sigma) was added for the final 2 hrs of activation. Cells were harvested in 54 55 FACs tubes and placed on ice, 7-amino-actinomycin D (4 µg/ml; Sigma) was added and cells were incubated for 10mins on ice. Cells were then washed with FACSFlow (BD Biosciences) 56 57 and processed for intracellular cytokine staining with Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer's instructions. Antibodies used (BD Biosciences unless stated 58 otherwise): PE anti IL-4 (Fastimmune). Allophycocyanin anti-IL-5 (TRFK5). PE anti-IL-13 59 (JES10-5A2), FITC anti-IFNy (B27). Samples were analysed on a FACSCalibur® (BD 60 Biosciences). Live cells were analysed for cytokine expression based upon forward and side 61 scatter and exclusion of 7-amino-actinomycin D. At least 10,000 live cells were analysed for 62 each sample. Quadrant markers were set based upon background staining of matched control 63 antibodies (also from BDBiosciences) and on resting, unactivated cells treated in parallel. 64

65

66 *Ex vivo* cell isolation

As a marker of *ex vivo* Th1 cells, CD3⁺CD4⁺IFN γ^+ cells were isolated from PBMCs using the 67 68 IFN_γ-FITC secretion assay detection kit (Miltenyi) in combination with anti-CD3 PE (BDBiosciences) anti-CD4-APC (Miltenvi) according to the manufacturer's instructions. Ex 69 70 *vivo* CD3⁺CD4⁺IL-13⁺ Th2 cells were isolated from PBMCs using the IL-13-PE secretion assay detection kit (Miltenyi), anti-CD3-FITC (BDBiosciences) and anti-CD4-APC 71 (BDBiosciences). To detect cytokine positive cells, PBMCs were activated for 3 hours using 72 PMA and Ionomycin prior to cell isolation according to the manufacturer's instructions. 73 74 Other *ex vivo* cell populations were isolated from blood by magnetic or FACs sorting using lineage specific markers. CD3+ (CD3+ cells); CD4+ (CD3+CD4+ cells); CD8+ (CD3+CD8+ 75

| 76 | cells); CD25+ (CD4+CD25+ cells); CD45RA+ (CD4+CD45RA+ cells), CD45RO+ |
|----|----------------------------------------------------------------------------------------------------------|
| 77 | (CD4+CD45RO+); NKT (CD3+CD56+ cells); NK (CD3-CD56+ cells); Monocyte (CD14+ |
| 78 | cells); APCs (CD3-CD19-CD14-CD56-HLA-DR+); B-cell (CD19+ cells); Basophil |
| 79 | (CD203c+); Granulocyte (Histopaque PMN pellet with RBC lysis); Neutrophil (CCR3- |
| 80 | granulocytes); Eosinophil (CCR3+granulocytes). Cells were FACS sorted on a FACS Aria |
| 81 | (BDBiosciences), purity post sort was greater than 85% in all experiments. Granulocyte |
| 82 | purities and morphologies were assessed by May-Grunwald Giemsa staining. |
| 83 | |
| 84 | |
| 85 | RNA isolation and RT-PCR |
| 86 | Isolation of total cellular RNA was performed using the RNeasy mini kit (Qiagen) according |
| 87 | to the manufacturer's instructions and reverse transcription was performed as previously |
| 88 | described ^{E2} . Quantitative real-time RT-PCR was performed using Taqman [®] MGB Gene |
| 89 | expression assays (Applied Biosystems). Probe sets used were: IL-4, Hs00929862_m1; IL-5, |
| 90 | Hs00174200_m1; IL-6, Hs00174131_m1; IL-10, Hs00174086_m1; IL-13, Hs00174379_m1; |
| 91 | IFNγ, Hs00174143_m1, FN1, Hs00277509_m1; FN1 EDA region, Hs01549959_m1; 18s |
| 92 | rRNA, Hs99999901_s1. Conventional RT-PCR was performed as previously described using |
| 93 | Amplitaq Gold Taq polymerase ¹ . Primers for amplifying the alternatively spliced regions of |
| 94 | FN1 were designed using MacVector and ordered from MWG Biotech. Primer sequences |
| 95 | were: EDB region, TACCACAACCCCTACAAACGGC and |
| 96 | TTTTCACAGGTGAGTAACGCACC; EDA and V region, |
| 97 | TCCCAGATGCAAGTGACCGATG and GGTAACAACCTCTTCCCGAACC. PCR |
| 98 | products were cloned into pCR 2.1 TOPO (Invitrogen) according to the manufacturer's |
| 99 | instructions and 40 individual clones of the FN1 regions were sequenced by Geneservice. |

Sequences have been deposited in GenBank, accession numbers: EF550130, EF550131,
EF550132, EF550133, EF550134, EF550135.

102

103 Microarray analysis

104 cRNA samples were prepared for microarray hybridisation to GeneChip U133 plus 2 arrays

105 according to the manufacturer's instructions (Affymetrix). Fragmented cRNA was hybridised

106 to GeneChip arrays at 45°C for 18 hours. Arrays were washed and stained with streptavidin-

107 PE according to the manufacturer's instructions on the GeneChip fluidics station 450

108 (Affymetrix). Fluorescent signals were detected using the GeneChip scanner 3000. Images

109 were analysed using the GeneChip operating software (GCOS, Affymetrix) to generate raw

110 data as .cel files. Further analysis was performed in GCOS to identify differentially expressed

111 genes. Data shown in Table 1 are representative of three independent biological replicates for

each condition.

| a 1. | | 1 |
|--------|----|-----------|
| Vondia | ot | <u> 1</u> |
| Sanurg | σι | aı |
| | | |

References

| 115 | | |
|-----|-----|--------------------------------------------------------------------------------------|
| 116 | E1. | Cousins DJ, Lee TH, Staynov DZ. Cytokine coexpression during human TH1/TH2 |
| 117 | | cell differentiation: direct evidence for coordinated expression of th2 cytokines. J |
| 118 | | Immunol 2002; 169:2498-506. |
| 119 | E2. | Gilmour J, Cousins DJ, Richards DF, Sattar Z, Lee TH, Lavender P. Regulation of |
| 120 | | GM-CSF expression by the transcription factor c-Maf. J Allergy Clin Immunol 2007; |
| 121 | | 120:56-63. |
| 122 | | |
| 123 | | |
| 124 | | |

125 Table

126 Table EI. Affymetrix GeneChip analysis of human Th1/Th2 cells

| Gene | Affymetrix | Th1 | Th2 | Fold | Th1 | Th2 | Fold |
|---------|-------------|---------|---------|------------|-----------|-----------|------------|
| Name | Probeset | Resting | Resting | Difference | Activated | Activated | Difference |
| FN1 | 211719_x_at | 2349.1 | 1.5 | 1566 | 1627.3 | 1.1 | 1479 |
| FN1 | 212464_s_at | 2052 | 1.7 | 1207 | 1184 | 1.7 | 696 |
| FN1 | 216442_x_at | 2186.1 | 2.6 | 840.8 | 1442.7 | 1.7 | 848.6 |
| COL13A1 | 208535_x_at | 7 | 22.5 | -3.21 | 1.5 | 1.8 | -1.2 |
| COL6A3 | 201438_at | 15.9 | 1 | 15.9 | 92.2 | 12.2 | 7.5 |
| FBN1 | 202766_s_at | 17.6 | 24.9 | -1.41 | 9.6 | 1.8 | 5.3 |
| FBN2 | 203184_at | 1.7 | 3.7 | -2.17 | 8.1 | 13.1 | -1.61 |
| LAMA1 | 227048_at | 9 | 0.4 | 22.5 | 8.7 | 5 | 1.74 |
| LAMC1 | 200771_at | 13.3 | 6.3 | 2.1 | 62.7 | 6.9 | 9.09 |
| ELN | 212670_at | 3.4 | 2.2 | 1.55 | 3.2 | 1.9 | 1.68 |
| ATIC | 208758_at | 669.5 | 521.7 | 1.28 | 1242.3 | 1184 | 1.05 |
| IL4 | 207539_s_at | 15.4 | 352.2 | -22.8 | 177.8 | 5197.8 | -29.2 |
| IL5 | 207952_at | 3.3 | 1219.5 | -369.5 | 3.5 | 11774.4 | -3364 |
| IL13 | 207844_at | 58.1 | 1504.4 | -25.9 | 409.3 | 10536.3 | -25.7 |
| IFNγ | 210354_at | 5905.7 | 70.9 | 83.3 | 12481.4 | 7906.1 | 1.58 |

127

128

129 Figure Legend

isolated from PBMCs and cultured for 28 days under Th1 or Th2 polarizing conditions.

132 Where indicated, cells were activated for 4 hours with PMA (5ng/ml) and ionomycin

¹³⁰ Figure E1. *In vitro* differentiation of human Th1 and Th2 cells. Naive CD4⁺ T-cells were

135

| 136 | Figure E2. Variable splicing of Th1 cell fibronectin. (A) Human fibronectin gene. Blue |
|-----|----------------------------------------------------------------------------------------------|
| 137 | boxes represent exons. Black boxes indicate regions of variable splicing; EDA, extra domain |
| 138 | A; EDB, extra domain B; VAR, variable region. (B) RT-PCR for EDB, EDA and variable |
| 139 | regions using primers indicated in C & D panels. (C & D) Variably spliced regions, red boxes |
| 140 | represent exons identified by sequencing. Frequency of exon splice variants (A-F) is shown. |
| 141 | (E) Coding sequence of Th1 cell fibronectin isoforms around the EDA and variable regions |
| 142 | (black boxes). (F) Alignments of the variable regions, LDV and REDV motifs are |
| 143 | highlighted. |

Repository - Unmarked E Figure No.1



Figure E1 Sandig et al.



Figure E2 Sandig et al.